Hp-002

Preclinical

SShanghai Helioson Pharmaceutical Co., Ltd.

Hp-002 is one of 14 therapeutic programs targeting B-cell Non Hodgkin Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell Non Hodgkin LymphomaNot yet recruiting

B-Cell Non Hodgkin LymphomaPreclinical

Not yet recruiting

Competition

Competitive Landscape

17 competitors in B-Cell Non Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

4 2

Oncovin

Eli Lilly

Phase 2

1 3

Adriamycin

Pfizer

Phase 2

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 5

Rayos

RRoxane Laboratories

Phase 2

3 6

Surovatamig

AstraZeneca

Phase 2

1 7

LUNSUMIO

Roche

Phase 1

1 8

Gazyva

Roche

Phase 1

1 9

Polivy

Roche

Phase 1

1 10

COLUMVI

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

PreclinicalNot yet recruiting

B-Cell Non Hodgkin Lymphoma

NCT07658352

Clinical

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

An Open-label, First-in-human Dose Escalation and Dose Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HP-002 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Not yet recruiting·SShanghai Helioson Pharmaceutical Co., Ltd.·Preclinical·NCT07658352·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hp-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hp-002. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Helioson Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShanghai Helioson Pharmaceutical Co., Ltd.

Hp-002

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News